Melatonin Reveals Oxytocin Deficiency in Hypopituitarism and Hypothalamic Injury
Overview
This study demonstrates that melatonin significantly increases oxytocin levels in healthy controls but not in patients with hypopituitarism and hypothalamic damage (HHD), indicating an impaired oxytocin response in HHD. The blunted oxytocin response correlates with increased depressive symptoms, alexithymia, anxiety, impaired sexual function, and reduced quality of life in affected patients.
Background
Hypopituitarism and hypothalamic damage (HHD) are associated with multiple comorbidities including psychopathology, alexithymia, sexual dysfunction, and reduced quality of life despite standard hormone replacement. Oxytocin (OXT), a neuropeptide synthesized in the hypothalamus and secreted by the posterior pituitary, plays a key role in psychological and social behaviors. Evidence suggests that oxytocin deficiency (OXT-D) may contribute to these symptoms in HHD, but reliable diagnostic tests for OXT-D are lacking. Melatonin (MEL), a neurohormone produced by the pineal gland, regulates OXT release in animal models and may serve as a safe and simple stimulus to reveal OXT deficiency in humans.
Data Highlights
Group
OXT Change at 90 min vs 0 min (pg/mL)
Percent Increase
95% CI
P Value
Healthy Controls (HCs)
14.57
26%
1.90 to 27.23
0.02
Hypopituitarism and Hypothalamic Damage (HHD)
Not significant
Not significant
Not significant
Not significant
Key Findings
Melatonin administration significantly increased plasma oxytocin levels at 90 minutes in healthy controls but not in patients with HHD.
The difference in oxytocin increase between HCs and HHD patients was 14.57 pg/mL, representing a 26% increase in HCs (P = .02).
Patients with HHD exhibited more depressive symptoms, alexithymia, impaired sexual function, and worse quality of life compared to healthy controls.
The percentage change in oxytocin from baseline to 90 minutes was negatively associated with depressive and alexithymia symptoms in the HHD group and with anxiety in both groups.
These findings support the presence of oxytocin deficiency in a subset of patients with HHD and suggest melatonin as a potential diagnostic tool for OXT-D.
Clinical Implications
Melatonin may serve as a safe, simple, and effective provocative test to identify oxytocin deficiency in patients with hypopituitarism and hypothalamic injury. Recognizing oxytocin deficiency could help explain persistent psychopathology and impaired quality of life in these patients despite standard hormone replacement, potentially guiding targeted therapeutic interventions. Further research is warranted to validate melatonin's diagnostic utility and explore oxytocin-based treatments.
Conclusion
This proof-of-concept study reveals a blunted oxytocin response to melatonin in patients with hypopituitarism and hypothalamic damage, supporting the existence of oxytocin deficiency in this population. Melatonin shows promise as a diagnostic stimulus to unmask oxytocin deficiency and its related clinical manifestations.
References
Clinical Research Article, 2023 -- Exploring Melatonin's Role in Revealing Oxytocin Deficiency in Hypopituitarism and Hypothalamic Injury
by Queralt Asla, Maite Garrido, Eulàlia Urgell, Sílvia Terzan, Alicia Santos, Nimmy Varghese, Cihan Atila, Betina Biagetti, Franziska Plessow, Mirjam Christ-Crain, Anne Eckert, Susan M Webb, Elizabeth A Lawson, Anna Aulinas
Swedish study finds two-way associations between premenstrual disorders and psychiatric conditions, with strongest links involving depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, and personality disorders.
